BATRA vs KYIV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong year-over-year earnings growth and solid operating margins, the company is unprofitable on net (negative profit margin and ROE), carries a high debt/equity ratio of 1.52, and shows poor liquidity with current and quick ratios below 1.0. Valuation metrics are stretched, with a negative forward P/E and a Price/Book of 4.80, while insider activity is decisively bearish, with recent selling by major shareholders. The stock has underperformed recently, down 13.4% over six months, and lacks analyst coverage, increasing uncertainty.
KYIV presents a complex value proposition characterized by a stable Piotroski F-Score of 4/9 and a significant valuation disconnect. While the stock trades at a deep discount to its Graham Number ($23.14) and possesses an exceptionally low Price-to-Book ratio of 0.28, this is offset by a bearish technical trend and negative YoY earnings growth (-13.40%). The strong revenue growth (28.40%) and a highly attractive forward P/E of 6.73 suggest a potential recovery, but the current lack of momentum and low intrinsic value estimate ($3.99) warrant a cautious approach.
Compare Another Pair
Related Comparisons
BATRA vs KYIV: Head-to-Head Comparison
This page compares Atlanta Braves Holdings, Inc. (BATRA) and Kyivstar Group Ltd. (KYIV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.